21 CFR 1271Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

21 CFR Part 1271 is the regulatory backbone for human cells, tissues, and cellular and tissue-based products in the United States. Issued under the Public Health Service Act, it sets infection-control safeguards and manufacturing expectations designed to prevent the introduction, transmission, and spread of communicable disease. The rule defines what an HCT/P is, who must register, how donors are evaluated, what current Good Tissue Practice requires, and when a product crosses into biologics or drug licensure.

At its core, Part 1271 does two things. First, it creates a baseline framework for establishments that recover, process, store, label, package, and distribute HCT/Ps, with concrete requirements for donor screening and testing, traceability, labeling, storage, and distribution controls. Second, through criteria in §1271.10(a), it draws a regulatory line between Section 361 HCT/Ps—regulated solely under Part 1271—and Section 351 products that require an investigational application and premarket approval as biologics or drugs.

For compliance leaders, correct scoping and early documentation are decisive. If a product truly meets the Section 361 criteria, the establishment must still prove robust donor eligibility determinations and maintain closed chain of custody. When a product depends on metabolic activity to achieve a systemic effect, or it is not used homologously, a biologics license path may be required, often alongside complex cell and gene therapy manufacturing controls.

Definitions and intent statements in Part 1271 must be read together with FDA guidance and inspection practice. Teams should build cross-functional, evidence-backed rationales for HCT/P classification and maintain durable records of donor eligibility, product characterization, and risk assessments to support inspections and field actions if needed.

Part 1271 applies to establishments that manufacture HCT/Ps, broadly defined to include recovery, donor screening and testing, processing, storage, labeling, packaging, and distribution. It captures a wide array of human tissues and cellular products, from birth-derived tissues to structural grafts and minimally manipulated cell suspensions, when they are intended for implantation, transplantation, infusion, or transfer into a human recipient.

The rule excludes certain categories managed under other authorities, such as vascularized human organs, whole blood and blood components for transfusion (regulated under 21 CFR 606), and products regulated as medical devices. Some HCT/Ps are subject to additional or alternative frameworks when used in specific ways. For example, unrelated allogeneic hematopoietic progenitor cells from umbilical cord blood used for hematopoietic reconstitution have historically proceeded under Section 351 licensure. These boundary conditions require early scoping and documented justification aligned to §1271.10(a) criteria.

Part 1271 also delineates narrow exemptions, including the same surgical procedure exception, where an HCT/P is removed and reimplanted in the same patient during the same procedure. These exemptions are interpreted strictly in inspections. Establishments working with birth tissue or other higher-risk sources should confirm how donor eligibility and labeling provisions apply, and ensure any transfer of custody preserves identity linkage, often through a robust chain of identity model.

Practical applicability turns on product intent and processing. A tissue marketed for support, cushioning, or barrier function has a different regulatory read than a cell suspension intended to treat systemic disease. Teams should memorialize these distinctions in product development plans, risk registers, and labeling rationales, and align operational controls with the expected HCT/P route to avoid late-stage reclassification.

The critical gateway in Part 1271 is §1271.10(a). An HCT/P regulated solely under Section 361 must be minimally manipulated, intended for homologous use, not combined with another article (with narrow exceptions for water, crystalloids, or sterilizing or preserving agents), and must not have a systemic effect or depend on the metabolic activity of living cells unless it is autologous, a first- or second-degree blood relative donation, or for reproductive use. Failure to meet any one criterion generally places the product into Section 351 biologics or drug territory.

Minimal manipulation is assessed differently for structural tissues and for cells and nonstructural tissues. Homologous use focuses on whether the product performs the same basic function in the recipient as in the donor. These determinations are context-dependent and must align with product claims, labeling, and actual clinical use. Establishments should document the scientific and clinical basis for these calls and maintain traceability from intended use to final labeling and distribution decisions.

Borderline products, especially those affecting systemic pathways or relying on living cell activity, increasingly sit within a biologics paradigm. Establishments should anticipate end-to-end documentation and traceability, from donor intake to disposition, including parameters like vein-to-vein time where relevant, to withstand classification scrutiny and inspections.

Subpart B of Part 1271 requires tissue establishments to register and list their HCT/Ps with FDA. Registration covers establishments that manufacture HCT/Ps, including recovery, screening, testing, processing, storage, labeling, packaging, or distribution. Listing describes the types of HCT/Ps manufactured. New establishments must register within the timeframes specified in §1271.22 and keep information current when operations, ownership, or activities change. Foreign establishments that import HCT/Ps into the United States must also register.

Registration and listing are not mere clerical steps. The information defines your inspected scope, links donor eligibility and cGTP obligations to product categories, and signals to FDA the risk profile of your operation. Inadequate, stale, or inconsistent listings expose establishments to enforcement and complicate recalls and lookbacks. The registration dossier should align with product descriptions, donor screening panels, process controls, and distribution pathways to ensure coherence during inspection.

Practical readiness means mapping organizational roles, ensuring your quality system references the registered activities, and maintaining controlled procedures and forms. Documented training, change control, and records retention plans must be anchored to the exact HCT/P types listed. A disciplined approach makes inspection responses faster and more credible, especially when paired with structured audit readiness, controlled document control, and an integrated QMS that unifies product, process, and personnel records.

Before first recovery or processing, validate data flows that feed registration and listing, including establishment identifiers, activities, and contacts. After any material change, verify submissions reflect the current state. Use internal audits to confirm that labels, donor eligibility determinations, and distribution records all reconcile to the listings on file.

Subpart C mandates donor eligibility determinations designed to mitigate communicable disease transmission. Establishments must screen donors using medical history, physical assessment, and risk factor evaluation, and must test for relevant communicable disease agents and diseases (RCDADs) using FDA-licensed, approved, or cleared tests performed in appropriately certified laboratories. The donor eligibility determination must be made by a responsible person based on documented screening and testing results, and it must precede release from quarantine.

The scope of screening and testing depends on the HCT/P type and donor circumstances. Certain autologous or reproductive HCT/Ps have specific provisions, but records and labeling requirements still apply. Establishments must maintain a complete donor record, including the donor risk assessment interview, test kit details, specimen collection dates and times, and any re-testing or supplemental testing performed. The donor eligibility summary must accompany the HCT/P at distribution, and any ineligible determinations must trigger documented controls, including restricted use or destruction as applicable.

Traceability depends on rigorous custody and identity management from recovery through final disposition. Implement tamper-evident packaging where appropriate, reconcile unique identifiers, and maintain unbroken chain of custody. When post-distribution information emerges, establishments must be able to perform rapid lookbacks to recipients and consignees and document corrective actions. Teams should rehearse these scenarios and maintain a plan consistent with donor eligibility lookback and deviation readiness.

Finally, train staff on escalation triggers. Any ambiguous medical history, specimen integrity concern, or discordant test result must be documented, investigated, and resolved before eligibility is finalized. If emergency use provisions are invoked, preserve the full paper and electronic trail for later review and recipient notification.

Subpart D codifies current Good Tissue Practice (cGTP): the methods, facilities, and controls used for manufacture to prevent introduction, transmission, or spread of communicable disease. It spans procedures, environmental control, supplies and reagents, equipment, recovery, processing, storage, labeling, packaging, distribution, returns, and complaint handling. Even for Section 361 HCT/Ps, the expectations are systemic and auditable, requiring training, deviation management, and documented release against defined criteria.

Key elements include defined responsibilities, validated cleaning and disinfection, environmental monitoring scaled to product risk, equipment qualification and maintenance, and segregation or quarantine controls. Labeling and packaging must preserve identity linkage and storage conditions. Process controls must be written, followed, and periodically challenged to verify continued suitability. Nonconformances require documented investigation and corrective actions with appropriate re-review of affected lots or donors.

Robust traceability stitches these elements together. Establishments should map identifiers from donor intake through disposition, maintain clear acceptance criteria for inputs and reagents, and reconcile movement and storage with temperature or time constraints. Digital systems can strengthen continuity, offering device-driven label formats, enforced steps, and immediate exception routing. Teams frequently complement cGTP with electronic records and signatures aligned to 21 CFR Part 11, laboratory controls via lab QC, and enforced workflows like step sequence enforcement to reduce human error.

Routine management review should track deviations, training effectiveness, and supplier performance. Strengthening traceability reduces the time to isolate affected units and supports inspection narratives that connect procedures, training, and outcomes.

Many compliance issues under Part 1271 arise from overbroad interpretations of minimal manipulation or homologous use, or from procedural gaps in donor eligibility and labeling. Borderline marketing claims can convert an otherwise homology-aligned product into a non-homologous use. Uncontrolled processing steps, unqualified environmental states, or inconsistent labeling chains often surface during inspections as systemic weaknesses. Early, written rationales anchored in the regulation and FDA guidance are essential to sustain a 361 classification.

Operationally, teams must prove that quarantine is enforced until an eligibility determination is complete, that test kits and laboratories meet regulatory expectations, and that each distribution is accompanied by a complete summary of donor records. Deviation investigations should include impact assessments for all potentially co-mingled materials or time-overlapped activities. When moving from experimental use toward scale, revalidate assumptions and claims to avoid implicit shifts in intended use.

• Asserting homologous use while making therapeutic claims that imply a new function
• Treating more-than-minimal processing steps as minimal manipulation
• Releasing from quarantine before final donor eligibility determination
• Using non-licensed or expired test kits for RCDADs
• Breaking identity linkage across labels, forms, or systems
• Relying on the same surgical procedure exception beyond its narrow boundaries
• Insufficient lookback capability for post-distribution information

When uncertainty persists, engage early with FDA and adjust documentation, labeling, and controls accordingly. For advanced therapies, plan for biologics pathways and align manufacturing with the rigor expected for cell and gene therapy manufacturing, including systemic control of identity, purity, potency, and safety.

Part 1271 sits within a broader ecosystem of manufacturing regulation. When a product fails §1271.10(a), it typically follows a biologics or drug pathway requiring cGMP under 21 CFR Parts 210 and 211. Combination products may engage both device and biologics regulations, with design and risk-management aspects influenced by device principles. Blood establishments and transfusion services follow 21 CFR 606, though some overlapping practices, such as donor history and testing controls, echo the aims of 1271.

Digital controls and quality systems increasingly bridge these regimes. Establishments often align electronic records and signatures to 21 CFR Part 11, while device-oriented quality planning under 21 CFR 820 and its transition to the FDA QMSR can inform structured documentation even for HCT/Ps. In Europe, cell and gene therapies align to advanced therapy medicinal product (ATMP) rules and GMP Part IV, discussed in ATMP GMP Part IV, creating parallel expectations for donor testing, traceability, and manufacturing control.

For reproductive and tissue banking accreditations, standards from AABB and AATB often supplement Part 1271 with granular procedural expectations. Where investigational or licensed biologics are involved, ICH quality guidelines shape modules on stability, validation, and control strategy. Cross-referencing these frameworks reduces duplication and ensures a coherent inspection posture when multiple authorities review the same establishment.

Teams should maintain regulatory maps that track when a program triggers a pivot from cGTP to cGMP, when labeling or claims affect homologous use, and how device or combination-product controls intersect with tissue practice. Where blood-derived steps exist, anchor responsibilities and records under 21 CFR 606, and where product development crosses into device lifecycles, align with planning norms described in medical device development phases.

Labeling must preserve identity linkage, storage and expiration conditions, and the donor eligibility summary. Distribution processes should verify consignee authorization, storage capabilities, and the presence of all required documents. Complaint handling systems must categorize events, triage for potential communicable disease risk, and initiate lookbacks or notifications when post-distribution information threatens recipient safety. Returns require quarantine and documented evaluation before any reintroduction or destruction.

Maintaining product-status visibility is a core expectation. Quarantine, release, hold-for-investigation, and recall statuses should be clearly differentiated and enforced in systems and physical storage. Temperature excursions, time-out-of-temperature limits, and transport integrity must be captured contemporaneously, with stability or suitability rationales documented. For chain-sensitive materials, reconciling identifiers through every handoff closes gaps that could compromise safety.

Establishments should run scheduled internal audits against Subparts B–D, sampling donor files, labeling packets, and distribution records. Performance indicators may include right-first-time eligibility determinations, time-to-quarantine-release, complaint cycle time, and lookback completion time. Digitalized workflows support immediate retrieval of donor records and distribution histories, and enable harmonized reporting during inspections and external audits.

Where a product category evolves or scales, assess whether claims, processing changes, or clinical use patterns alter homologous use or minimal manipulation assumptions. Adjust registration and listing, labeling, and procedures promptly and document the rationale. Integration with traceability tools and controlled document repositories reduces the risk of misalignment between intent and execution.

Implementing Part 1271 reliably requires tight integration of donor eligibility, cGTP procedures, labeling, and distribution records. V5 Ultimate unifies these workflows in a validated environment, tying donor screening and testing to product identifiers, enforcing quarantine and release logic, and maintaining an immutable audit trail. Establishments can configure stepwise procedures, link training to role-based permissions, and deploy device-driven labeling that preserves identity and storage requirements across the product lifecycle.

Our platform strengthens traceability with end-to-end identifier management and rapid lookback capability. Teams can capture environmental data, equipment qualification and calibration records, and nonconformance investigations in one system. Electronic records and signatures align to Part 11 controls, and structured deviations route to quality for impact analysis before product release. Supplier and consignee onboarding, status-controlled distribution, and shareable inspection packets compress inspection prep from weeks to hours.

For programs that cross into biologics pathways, V5 scales with additional controls for batch release, lab data, and validation packages, supporting a clean transition from cGTP to cGMP expectations. Prebuilt templates and analytics speed readiness for FDA inspections and third-party accreditation while keeping product, process, and personnel data reconciled.